

## Nepal

### Support for Vaccine: Pentavalent (DTP-HepB-Hib) This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b>	Nepal						
<b>2. Vaccine grant number:</b>	08-NPL-08b-Y, 1215-NPL-04C-X, 16-NPL-04c-X, 17-NPL-04c-X, 1821-NPL-04c-X						
<b>3. Date of Decision Letter:</b>	30/09/2019						
<b>4. Date of the Partnership Framework Agreement:</b>	22 August 2014						
<b>5. Programme title:</b>	New Vaccine Support (NVS), DTP-HepB-Hib, Routine						
<b>6. Vaccine type:</b>	DTP-HepB-Hib						
<b>7. Requested product presentation and formulation of vaccine:</b>	Penta, 10 dose(s) per vial, LIQUID						
<b>8. Programme Duration:<sup>1</sup></b>	2009-2021						
<b>9. Programme Budget (indicative):<sup>2</sup></b>	(subject to the terms of the Partnership Framework Agreement, if applicable)						
	2009-2019	2020	2021	2022	2023	2024	Total <sup>2</sup>
Programme Budget (US\$)	49,509,879	790,000	1,169,000	-	-	-	51,468,879
<b>10. Vaccine introduction grant</b>							
	<b>Approval</b>						
	<b>Year</b>	<b>Grant Number</b>	<b>Amount (US\$)</b>				
	2008	08-NPL-08b-Y	266,500				
	<b>Disbursement</b>						
	<b>Disbursement date</b>		<b>Amount (US\$)</b>				
	07 August, 2008		266,500				
<b>11. Product switch grant</b>	Not applicable						
<b>12. Indicative Annual Amounts:<sup>3</sup></b>	(subject to the terms of the Partnership Framework Agreement, if applicable)						
<b>Type of supplies to be purchased with Gavi funds</b>	<b>2009-2019</b>	<b>2020</b>	<b>2021</b>				
Number of vaccine doses		1,093,500	-				
Annual Amounts (US\$)	49,509,879	790,000	-				

<sup>1</sup> This is the entire duration of the programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the programme.

<sup>3</sup> This is the amount that Gavi has approved.

<b>13. Procurement agency:</b>	UNICEF. The Country shall release its co-financing payments each year to UNICEF.																																										
<b>14. Self-procurement:</b>	Not applicable																																										
<b>15. Co-financing obligations:</b>	<p>According to the co-financing policy, the Country falls within the group: Initial self-financing</p> <p>The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p> <table border="1"> <thead> <tr> <th>Type of supplies to be purchased with Country funds in each year</th> <th>2020</th> <th>2021</th> <th>2022</th> <th>2023</th> <th>2024</th> </tr> </thead> <tbody> <tr> <td>Number of vaccine doses</td> <td>419,500</td> <td>620,500</td> <td>-</td> <td>-</td> <td>-</td> </tr> <tr> <td>Number of AD syringes</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> </tr> <tr> <td>Number of re-constitution syringes</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> </tr> <tr> <td>Number of safety boxes</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td>293,447</td> <td>434,324</td> <td>-</td> <td>-</td> <td>-</td> </tr> <tr> <td>Total co-financing payments (US\$) (including freight)</td> <td>303,000</td> <td>448,000</td> <td>-</td> <td>-</td> <td>-</td> </tr> </tbody> </table>	Type of supplies to be purchased with Country funds in each year	2020	2021	2022	2023	2024	Number of vaccine doses	419,500	620,500	-	-	-	Number of AD syringes	-	-	-	-	-	Number of re-constitution syringes	-	-	-	-	-	Number of safety boxes	-	-	-	-	-	Value of vaccine doses (US\$)	293,447	434,324	-	-	-	Total co-financing payments (US\$) (including freight)	303,000	448,000	-	-	-
Type of supplies to be purchased with Country funds in each year	2020	2021	2022	2023	2024																																						
Number of vaccine doses	419,500	620,500	-	-	-																																						
Number of AD syringes	-	-	-	-	-																																						
Number of re-constitution syringes	-	-	-	-	-																																						
Number of safety boxes	-	-	-	-	-																																						
Value of vaccine doses (US\$)	293,447	434,324	-	-	-																																						
Total co-financing payments (US\$) (including freight)	303,000	448,000	-	-	-																																						
<b>16. Operational support for campaigns:</b>	Not applicable																																										
<b>17. Additional Reporting Requirements:</b>	<table border="1"> <thead> <tr> <th></th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> <li>vaccine stock levels including buffer stock, by end of March;</li> <li>number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May.</li> <li>Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul> </td> <td> 31 March 2020  15 May 2020 </td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Gavi Secretariat</td> </tr> </tbody> </table>		Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> <li>vaccine stock levels including buffer stock, by end of March;</li> <li>number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May.</li> <li>Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul>	31 March 2020 15 May 2020	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat																																				
	Due dates																																										
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> <li>vaccine stock levels including buffer stock, by end of March;</li> <li>number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May.</li> <li>Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul>	31 March 2020 15 May 2020																																										
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat																																										
<b>18. Financial clarifications:</b>	<p>Country shall provide the following clarifications to Gavi*:</p> <p>Not applicable</p> <p>* Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements.</p>																																										

**19. Other conditions:**

Not applicable

*Signed by,*

**On behalf of Gavi**



Thabani Maphosa  
Managing Director, Country Programmes  
30 September 2019